September 18, 2023
ASEPTIC PROCESS OF VIRAL VECTOR-BASED VACCINES – KEY ASPECTS TO CONSIDER BEFORE CLINICAL MANUFACTURING
Authors: Dr Cristina URECHE (Business Development Manager at ABL Europe) and Guillaume SIRGUE (Head of Biomanufacturing and Process Development Operations at ABL Europe)
Article published in Drug Target Review (Issue 3, September 2023)
Aseptic processing is crucial for the cGMP manufacturing of viral vector-based vaccines, such as measles or poxviruses, that cannot be terminally sterilised. This requires careful consideration of various factors: air cleanliness, personnel training and validation. Here, experts Dr Cristina Ureche and Guillaume Sirgue explain how, by adhering to certain requirements, developers can produce safe and sterile products for clinical trials.
To read more, please visit the dedicated page of the drugtargetreview.com website.